Portola Unruffled By NICE’s Rejection Of Ondexxya
Executive Summary
Although the health technology assessment institute for England has provisionally recommended against the use of Europe’s first and only approved drug for reversing the effects of factor Xa anticoagulants, Portola believes it may now have the evidence needed to reverse this decision.